Responses

Download PDFPDF

Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case–control comparison
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Reply to “Concerns regarding the inference that EDS is not rare"
    • Joanne C Demmler, Lecturer Health Data Research UK, Swansea University
    • Other Contributors:
      • Mark D Atkinson,, Research Officer, Secure Anonymised Information Linkage (SAIL) Databank
      • Emma J Reinhold, RCGP Clinical Champion for the Ehlers-Danlos Syndromes
      • Ernest Choy, Professor, Arthritis Research UK CREATE Centre, Section of Rheumatology, Division of Infection and Immunity
      • Ronan A Lyons, Professor, Health Data Research UK

    We would like to thank Hakim et al for the opportunity to continue the debate around the prevalence and definitions of conditions associated with joint hypermobility. Coming to anything like a true population prevalence for these conditions is still a long way off due to both the huge under-diagnosis (1) and ongoing evolution of the clinically-based criteria (2-4) and terminology for patients who do not have one of the known genetic mutations for classical, vascular or the other so-called rare subtypes of Ehlers-Danlos Syndrome (EDS).

    Hakim et al assert in their letter that diagnosed Joint Hypermobility Syndrome (JHS) is known to be ‘common’. We have searched the literature for reported whole population prevalence rates for JHS and have been unable to find any. Therefore our paper is the first to report a diagnosed prevalence for this condition, although this figure can also be derived for the population of Sweden, as we pointed out in our work. (5)

    We completely agree with the letter’s authors that at this point in time it is not possible to know what proportion of people who met the Brighton Criteria for JHS also meet the 2017 hEDS criteria. We hope further research may reveal this data in the future. What we can say, however, is that for the decade or so prior to 2017, experts in the field considered JHS and EDS-HT to be clinically indistinguishable (1, 6-10), indeed many clinicians used the term JHS/EDS-HT in correspondence in recognition of this. Indeed,...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Concerns regarding the inference that EDS is not rare
    • Alan J Hakim, Adjunct Associate Professor in Medicine College of Medicine, PennState University, USA
    • Other Contributors:
      • Clair A Francomano, Professor of Medical and Molecular Genetics
      • Marco Castori, Consultant and Director, Division of Medical Genetics
      • Fransiska Malfait, Associate Professor

    Dear Sir or Madam

    Re. Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison.
    Demmler J C, Atkinson M D, Reinhold E, Choy E, Lyons R A, Brophy S T
    BMJ Open 2019;9:e031365

    We write concerning the paper by Demmler et al., published in BMJ Open. We wish to raise the following concerns:

    1. With regard to combining the Joint Hypermobility Syndrome (JHS) and Ehlers-Danlos syndromes (EDS) populations for analysis.

    If one combines data from a cohort that is found to be ‘common’ (in this case ‘diagnosed JHS’) with one that is found to be ‘rare’ (in this case ‘diagnosed EDS’), the new combined cohort (i.e. diagnosed JHS/EDS) will be common. To then consider the rare cohort common is a fallacy.

    Also, although individuals in a population with a previous diagnosis of JHS (i.e. prior to the 2017 international classification (1,2)) might have Hypermobile EDS (hEDS) by the current classification, it is not known how JHS segregates into Hypermobility Spectrum Disorder (HSD) and hEDS. A JHS population would need to be reassessed to confirm this, or modelling assumptions of the data would need to be applied.
    In addition, it is not known what proportion of the EDS cohort have hEDS versus the rare Mendelian types of EDS. As such, there is no way of knowing whether or by what proportion the two cohorts represent the same or similar or dif...

    Show More
    Conflict of Interest:
    None declared.